Market openADR
I-MAB/$IMAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
Ticker
$IMAB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
32
ISIN
US44975P1030
Website
I-MAB Metrics
BasicAdvanced
$73M
-
-$0.11
-
-
Price and volume
Market cap
$73M
52-week high
$2.00
52-week low
$0.60
Average daily volume
198K
Financial strength
Current ratio
22.35
Quick ratio
21.755
Long term debt to equity
1.436
Total debt to equity
1.857
Management effectiveness
Valuation
Price to book
0.37
Price to tangible book (TTM)
0.37
Growth
Earnings per share change (TTM)
-94.18%
3-year earnings per share growth (CAGR)
-69.91%
What the Analysts think about I-MAB
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for I-MAB stock.
I-MAB Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
I-MAB Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
I-MAB News
AllArticlesVideos
I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
GlobeNewsWire·2 months ago
I-Mab Announces Accelerated Givastomig Phase 1b Study Progress
GlobeNewsWire·2 months ago
I-Mab to Participate in Leerink Partners Global Healthcare Conference
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for I-MAB stock?
I-MAB (IMAB) has a market cap of $73M as of May 19, 2025.
What is the P/E ratio for I-MAB stock?
The price to earnings (P/E) ratio for I-MAB (IMAB) stock is 0 as of May 19, 2025.
Does I-MAB stock pay dividends?
No, I-MAB (IMAB) stock does not pay dividends to its shareholders as of May 19, 2025.
When is the next I-MAB dividend payment date?
I-MAB (IMAB) stock does not pay dividends to its shareholders.
What is the beta indicator for I-MAB?
I-MAB (IMAB) does not currently have a Beta indicator.